Melatonin Mitigates Sarcopenic Obesity via Microbiota and Short‐Chain Fatty Acids: Evidence From Epidemiologic and In Vivo Studies

Xiaoxing Mo, Lihui Shen, Xinyu Wang, Wenqing Ni, Linyan Li, Lili Xia, Hongjie Liu, Ruijie Cheng, Wen Lin, Jianming Xu, Liegang LiuJournal of Cachexia Sarcopenia and Muscle 2025 · DOI

TL;DR

This study reveals that melatonin (MLT) can combat sarcopenic obesity (SO) by positively influencing the gut microbiome and increasing short-chain fatty acids (SCFAs). These findings suggest MLT could be a novel therapeutic strategy to prevent or delay the progression of SO, a growing health concern.

What Problem Does This Paper Address?

Sarcopenic obesity (SO) is a complex condition characterized by the simultaneous presence of obesity and sarcopenia (loss of muscle mass, strength, and function). It significantly increases the risk of disability, fractures, and metabolic diseases, particularly in aging populations. While high-fat diets (HFDs) are known contributors to SO, effective preventive and therapeutic strategies remain insufficient. Emerging research points to the gut microbiome and its metabolites as key players in SO development. Specifically, HFD-induced gut dysbiosis can trigger inflammation and oxidative stress, leading to muscle atrophy. Melatonin (MLT), a hormone with known antioxidant and anti-inflammatory properties, has shown promise in improving muscle health. However, its specific role in mitigating SO, particularly through its interaction with the gut microbiota and SCFAs, has not been fully elucidated. This paper aims to bridge this knowledge gap by investigating the effects of MLT on SO, focusing on its impact on the gut microbiome and SCFAs.

Methods

The study employed a multi-pronged approach:

  • Case-Control Study: To establish an initial link between MLT levels and SO, researchers compared serum MLT levels in 31 patients with SO against a control group.
  • In Vivo Animal Model: A high-fat diet (HFD) was used to induce SO in 12-month-old female Sprague-Dawley rats. These rats were then treated with MLT for 16 weeks.
  • Gut Microbiota Analysis: 16S rRNA gene sequencing was used to analyze the composition and diversity of the gut microbiota in the rats.
  • Metabolite Analysis: Gas chromatography-mass spectrometry was employed to quantify short-chain fatty acids (SCFAs) in fecal and serum samples.
  • Gut Barrier Integrity Assessment: The expression of key proteins like Muc-2 and tight junction proteins (claudin-1, occludin, zonula occluden-1) was measured to evaluate gut barrier function.
  • Functional Assays:
    • Faecal Microbiota Transplantation (FMT): To confirm the causal role of the gut microbiota, fecal samples from MLT-treated rats were transplanted into recipient rats.
  • SCFA Administration: To directly assess the impact of SCFAs, a mixture of acetate, propionate, and butyrate was administered to HFD-fed rats.
  • Physiological and Biochemical Assessments: Various tests were conducted, including body weight and food intake monitoring, oral glucose tolerance tests (OGTT), intraperitoneal insulin tolerance tests (ipITT), muscle strength and function tests (rotarod, grip strength, exhaustive running), muscle atrophy assessment (histology, gene expression of atrophy markers), and analysis of protein synthesis pathways (AKT/mTOR/p70S6k).

Datasets

Not explicitly detailed as distinct datasets for training/evaluation in the context of machine learning. The study utilized:

  • Human Cohort Data: Data from 31 SO patients and 31 age- and sex-matched controls from the Shenzhen Ageing Cohort Study (SZ-ageing).
  • Animal Model Data: Data generated from Sprague-Dawley rats subjected to HFD and/or MLT treatment, FMT, and SCFA administration.

Key Insights and Ideas

  • MLT Deficiency in SO: The study found significantly lower serum MLT levels in patients with SO, suggesting a potential link between MLT deficiency and the development of this condition.
  • MLT's Gut-Muscle Axis: The research strongly supports a mechanism where MLT influences SO by modulating the gut microbiome and its SCFA production, which in turn impacts muscle health and metabolic function.
  • SCFAs as Key Mediators: SCFAs emerged as crucial mediators of MLT's beneficial effects, directly influencing muscle protein synthesis, reducing oxidative stress, and improving metabolic parameters.
  • Gut Barrier Restoration: MLT's ability to repair the gut barrier by increasing protective proteins like Muc-2 and tight junction proteins is a significant finding, suggesting a role in preventing systemic inflammation.
  • Microbiota Signatures of SO: The study identified specific gut bacteria (e.g., increased Firmicutes, decreased Bacteroidetes in HFD-fed rats) associated with SO, and demonstrated that MLT could restore a healthier microbial profile.

Key Results

  • Human Study: Serum MLT levels were lower in SO patients (p<0.01) and positively correlated with appendicular skeletal muscle mass index (r=0.3514, p<0.01) and handgrip strength (r=0.2824, p<0.05).
  • Animal Study (MLT Intervention): MLT treatment in HFD-fed rats significantly ameliorated obesity-related metabolic disorders, improved muscle mass, strength, and function, and reduced muscle atrophy.
  • Microbiome Modulation: MLT normalized HFD-induced gut dysbiosis, increasing beneficial SCFA-producing bacteria and SCFAs (acetate, propionate, butyrate) in both feces and serum (p<0.05).
  • Gut Barrier Repair: MLT promoted the expression of Muc-2, claudin-1, occludin, and zonula occluden-1 proteins in the colon (p<0.05).
  • FMT Efficacy: Faecal suspension from MLT-treated rats partially mitigated metabolic disorders, poor muscle mass and function, and muscle atrophy in recipient rats (p<0.05).
  • SCFA Efficacy: SCFA treatment in HFD-fed rats alleviated SO by suppressing metabolic disorders, reducing muscle oxidative stress and inflammation, and promoting protein synthesis via the AKT/mTOR/p70S6k pathway (p<0.05).

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The case-control study had a relatively small sample size, necessitating larger studies with adjustments for confounding variables to further elucidate the MLT-SO association.
  • Detailed SCFA Mechanisms: Further research is needed to fully understand the detailed mechanisms by which SCFAs regulate the AKT/mTOR/p70S6k signaling pathway.
  • Microbiota Resolution: While 16S rRNA gene sequencing provided valuable insights, higher-resolution methods like ASV analysis are recommended for characterizing taxon-specific responses to MLT.
  • Gender Differences: The study primarily focused on female rats. Further investigation into the effects of MLT on SO in different genders is warranted.

Future work should focus on these areas to build upon the promising findings of this study and translate them into effective clinical interventions.

Summary updated

Abstract

MLT mitigated HFD-induced SO by regulating the gut microbiota and promoting the production of SCFAs. MLT might be a novel strategy for delaying the progression of SO.
BibTeX
@article{mo2025melatonin,
  author = {Xiaoxing Mo and Lihui Shen and Xinyu Wang and Wenqing Ni and Linyan Li and Lili Xia and Hongjie Liu and Ruijie Cheng and Wen Lin and Jianming Xu and Liegang Liu},
  title = {{Melatonin Mitigates Sarcopenic Obesity via Microbiota and Short‐Chain Fatty Acids: Evidence From Epidemiologic and In Vivo Studies}},
  journal = {Journal of Cachexia Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13869},
}
Figure